4 results on '"Zan Shen"'
Search Results
2. Significance of HIFU in local unresectable recurrence of soft tissue sarcoma, a single-center, respective, case series in China
- Author
-
Zan Shen, Lixin Jiang, Li-Na Tang, Feng Lin, and Wenxi Yu
- Subjects
Adult ,Male ,China ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Single Center ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Child ,Aged ,Retrospective Studies ,Response rate (survey) ,medicine.diagnostic_test ,business.industry ,Soft tissue sarcoma ,Rate control ,Sarcoma ,Magnetic resonance imaging ,Retrospective cohort study ,Middle Aged ,Prognosis ,Ablation ,medicine.disease ,High-intensity focused ultrasound ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,High-Intensity Focused Ultrasound Ablation ,Female ,Surgery ,Radiology ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Purpose Multimodality treatment of soft tissue sarcoma(STS) by expert teams reportedly affords a tremendous improvement in outcome of patients. Despite advances, treatment of local unresectable recurrence remains difficult and is not standardized. We performed this retrospective study in order to assess the efficacy and safety of high-intensity focused ultrasound (HIFU) ablation in treating STS patients with local unresectable recurrence. Methods Thirty-six STS patients with local unresectable recurrence from January 2015 to December 2016 were recruited according to the inclusion criteria. Pain rating, response rate, disease control rate, local disease progression-free survival(LPFS), progression-free survival (PFS) and overall survival(OS) were used to evaluate efficacy of HIFU treatment. Results HIFU resulted in a significant relief in pain rating, without severe side effects. According to magnetic resonance imaging(MRI), three months after HIFU treatment, response rate was 47.3% and the local disease control rate was 80.6%. Twelve months post HIFU treatment, response rate was 38.9% and the local disease control rate was 55.6%. The median LPFS, PFS and OS time for 36 patients was 13 months, 10 months and 20 months respectively. Conclusion HIFU is a tolerated treatment modality with promising activity and safety in STS patients with local unresectable recurrence.
- Published
- 2019
3. High-intensity focused ultrasound: noninvasive treatment for local unresectable recurrence of osteosarcoma
- Author
-
Li-Na Tang, Zan Shen, Xiao-hui Zhou, Wenxi Yu, Feng Lin, and Yang Yao
- Subjects
Adult ,Male ,medicine.medical_specialty ,China ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Disease ,Focused ultrasound ,Young Adult ,Stable Disease ,Medicine ,Pulmonary metastasis ,Humans ,Child ,Response Evaluation Criteria in Solid Tumors ,Retrospective Studies ,Response rate (survey) ,Osteosarcoma ,business.industry ,Middle Aged ,medicine.disease ,High-intensity focused ultrasound ,Surgery ,Oncology ,Hifu treatment ,High-Intensity Focused Ultrasound Ablation ,Female ,Radiology ,Neoplasm Recurrence, Local ,business - Abstract
Objective Local unresectable recurrence of osteosarcoma is one of the most challenging tumors to treat. High-intensity focused ultrasound (HIFU) is a new, noninvasive technique with potential to ablate and inactivate tumors. Treatment of solid tumors with HIFU has been reported. In this study, we assessed safety and efficacy of HIFU in treating local unresectable recurrence of osteosarcoma. Methods We performed a retrospective analysis of 27 patients who had local unresectable recurrence of osteosarcoma from 2006 to 2010. Changes of biochemical markers and pain rating, response rate, disease control rate, local disease progression-free survival, progression-free survival (PFS) and overall survival (OS) were used to evaluate efficacy of HIFU treatment. Results HIFU resulted in a significant change in alkaline phosphatase and lactic acid dehydrogenase and a remarkably relief in pain rating, without severe side effects. According to MRI examination 4โ6 weeks after HIFU treatment, 2 (7.4%) patients had complete response (CR), 12 (44.4%) had partial response (PR), 9 (33.3%) had stable disease (SD) and 4 (14.8%) had progression disease (PD). The response rate was 51.8% and the local disease control rate was 85.2%. The 1-, 2-, and 3-year local disease control rates were 59.2%, 40.7% and 33.1%, respectively. The median local disease progression-free time was 14 months, the median progression-free time was 13 months and the median over-all survival time was 21 months. Patients without pulmonary metastasis had a better local disease control rate at 1-,2-,3-year and a longer local disease progression-free time, progression-free time, over-all survival time than patients with pulmonary metastasis. Conclusion HIFU is a safe and noninvasive treatment for local unresectable recurrence of osteosarcoma, with good local control and without severe complications.
- Published
- 2014
4. High-intensity focused ultrasound: Noninvasive treatment for local unresectable recurrence of osteosarcoma.
- Author
-
Wenxi Yu, Lina Tang, Feng Lin, Yang Yao, Zan Shen, and Xiaohui Zhou
- Subjects
- *
OSTEOSARCOMA , *NONINVASIVE diagnostic tests , *HIGH-intensity focused ultrasound , *TUMOR diagnosis , *RETROSPECTIVE studies , *DEHYDROGENASES - Abstract
Objective: Local unresectable recurrence of osteosarcoma is one of the most challenging tumors to treat. High-intensity focused ultrasound (HIFU) is a new, noninvasive technique with potential to ablate and inactivate tumors. Treatment of solid tumors with HIFU has been reported. In this study, we assessed safety and efficacy of HIFU in treating local unresectable recurrence of osteosarcoma. Methods: We performed a retrospective analysis of 27 patients who had local unresectable recurrence of osteosarcoma from 2006 to 2010. Changes of biochemical markers and pain rating, response rate, disease control rate, local disease progression-free survival, progression-free survival (PFS) and overall survival (OS) were used to evaluate efficacy of HIFU treatment. Results: HIFU resulted in a significant change in alkaline phosphatase and lactic acid dehydrogenase and a remarkably relief in pain rating, without severe side effects. According to MRI examination 4e6 weeks after HIFU treatment, 2 (7.4%) patients had complete response (CR), 12 (44.4%) had partial response (PR), 9 (33.3%) had stable disease (SD) and 4 (14.8%) had progression disease (PD). The response rate was 51.8% and the local disease control rate was 85.2%. The 1-, 2-, and 3-year local disease control rates were 59.2%, 40.7% and 33.1%, respectively. The median local disease progression-free time was 14 months, the median progression-free time was 13 months and the median over-all survival time was 21 months. Patients without pulmonary metastasis had a better local disease control rate at 1-,2-,3-year and a longer local disease progression-free time, progression-free time, over-all survival time than patients with pulmonary metastasis. Conclusion: HIFU is a safe and noninvasive treatment for local unresectable recurrence of osteosarcoma, with good local control and without severe complications. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.